

## Special Issue

# The Current and Future Status of Personalized Medicine for Gynecologic Cancers

### Message from the Guest Editors

Dear colleagues, Our special issue will give both an historical and an up to the minute overview of the status of personalized medicine in gynecologic oncology. We will first review the current status of FDA-approved targeted therapies in gynecologic malignancies.

Manuscripts will be solicited from top experts in the field covering (1) how big data has helped us define the unique characteristics of gynecologic malignancies that predict for response to treatments, (2) current precision agents in use, including anti-angiogenics, PARP inhibitors and hormonal therapy, and (3) new biomarkers that may enhance our ability to further personalize treatments. Finally, the use of novel, personalized patient avatars such as organoids will be described. We will emphasize that organoid cell cultures represent a new technology with the potential to become a powerful functional prediction model for treatment responsiveness that is unique to every patient.

---

### Guest Editors

Prof. Dr. Kimberly Leslie

Prof. Dr. David G. Mutch

Prof. Dr. Doris M. Benbrook

Dr. Kristina W. Thiel

---

### Deadline for manuscript submissions

closed (1 April 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.4**  
**CiteScore 8.8**  
**Indexed in PubMed**



[mdpi.com/si/58512](https://mdpi.com/si/58512)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)